This article was originally published in The Gray Sheet
Monoclonal antibody platelet glycoprotein IIb/IIIa inhibitor ReoPro with stenting reduces risk of death or heart attack by 51% at six-months compared to use of stents alone, according to results released from the EPISTENT trial. The 2,399 patient, 63-center trial, primarily using J&J's Palmaz-Schatz stent, randomized patients with ischemic heart disease to either stenting with placebo, stenting with ReoPro or angioplasty with ReoPro. A sustained six-month 31% reduction in death and heart attack also was shown using ReoPro and angioplasty compared to stenting alone
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.